Search - tctmd.com

Displaying 1 - 20 of 23

Sort: Relevancy | Date

My Takeaways From EuroPCR 2017: Everything Perfect, Until It’s Not

News Conference News EuroPCR 2017

My Takeaways From EuroPCR 2017: Everything Perfect, Until It’s Not

June 02, 2017

Embolic Protection During TAVR Reduces Volume of Cerebral Lesions, but Clinical Benefit Not Evident: Meta-analysis

News Conference News EuroPCR 2017

Embolic Protection During TAVR Reduces Volume of Cerebral Lesions, but Clinical Benefit Not Evident: Meta-analysis

Michael O'Riordan

May 26, 2017

EWOLUTION Analysis Backs LAA Closure in High-Risk Patients Taking DAPT, Not Warfarin, After Procedure

News Conference News EuroPCR 2017

EWOLUTION Analysis Backs LAA Closure in High-Risk Patients Taking DAPT, Not Warfarin, After Procedure

Michael O'Riordan

May 24, 2017

DISRUPT CAD: Lithoplasty May Modify Dense Calcium in Coronary Lesions Before Stenting

News Conference News EuroPCR 2017

DISRUPT CAD: Lithoplasty May Modify Dense Calcium in Coronary Lesions Before Stenting

Yael L. Maxwell

May 22, 2017

Best Antiplatelet Therapy in Real-World PCI? European Registries Fuel the Debate

News Conference News EuroPCR 2017

Best Antiplatelet Therapy in Real-World PCI? European Registries Fuel the Debate

May 22, 2017

Slimmest Stent to Date Looks Promising in Small Study

News Conference News EuroPCR 2017

Slimmest Stent to Date Looks Promising in Small Study

May 19, 2017

Scaffold Thrombosis ‘Unpredictable’ With Absorb: AIDA Analysis

News Conference News EuroPCR 2017

Scaffold Thrombosis ‘Unpredictable’ With Absorb: AIDA Analysis

Michael O'Riordan

May 19, 2017

News Conference News EuroPCR 2017

Transradial PCI in ACS Reduces Risk of Acute Kidney Injury

Michael O'Riordan

May 18, 2017

More Early Stroke With SAVR Than TAVR in SURTAVI

News Conference News EuroPCR 2017

More Early Stroke With SAVR Than TAVR in SURTAVI

May 18, 2017

EUROCTO: Revascularization Bests Medical Therapy for Quality of Life in CTO Lesions

News Conference News EuroPCR 2017

EUROCTO: Revascularization Bests Medical Therapy for Quality of Life in CTO Lesions

Yael L. Maxwell

May 18, 2017

FFR-SEARCH Explores Potential of Physiologic Assessment After PCI

News Conference News EuroPCR 2017

FFR-SEARCH Explores Potential of Physiologic Assessment After PCI

May 18, 2017

BIO-RESORT: Impaired Glucose Metabolism Linked With Worse Clinical Outcomes After PCI

News Conference News EuroPCR 2017

BIO-RESORT: Impaired Glucose Metabolism Linked With Worse Clinical Outcomes After PCI

Michael O'Riordan

May 18, 2017

TAVR Durability: Some Reassurances From CoreValve Trials Out to 9 Years

News Conference News EuroPCR 2017

TAVR Durability: Some Reassurances From CoreValve Trials Out to 9 Years

May 17, 2017

News Conference News EuroPCR 2017

Bicuspid AS Patients with Calcification Fare Worse After TAVR, But Device Type Matters

Michael O'Riordan

May 17, 2017

If They Survive First Month, Mitral Annular Calcification Patients Treated With Transcatheter Valves Do Well at 1 Year

News Conference News EuroPCR 2017

If They Survive First Month, Mitral Annular Calcification Patients Treated With Transcatheter Valves Do Well at 1 Year

May 17, 2017

The ARTE of Antiplatelet Therapy After TAVR: Bleeding Greater with Clopidogrel Plus Aspirin vs Aspirin Alone

News Conference News EuroPCR 2017

The ARTE of Antiplatelet Therapy After TAVR: Bleeding Greater with Clopidogrel Plus Aspirin vs Aspirin Alone

Yael L. Maxwell

May 17, 2017

No Very Late Scaffold Thrombosis Risk With Absorb BVS in China, Japan

News Conference News EuroPCR 2017

No Very Late Scaffold Thrombosis Risk With Absorb BVS Studies in China, Japan

Michael O'Riordan

May 17, 2017

REPRISE III: Lotus Valve Matches CoreValve in First Head-to-Head TAVR Trial

News Conference News EuroPCR 2017

REPRISE III: Lotus Valve Matches CoreValve in First, Large Head-to-Head TAVR Trial

May 16, 2017

iFR and FFR Equally Safe for Deferring Revascularization, Pooled Analysis Shows

News Conference News EuroPCR 2017

iFR and FFR Equally Safe for Deferring Revascularization, Pooled Analysis Shows

May 16, 2017

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

News Conference News EuroPCR 2017

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

Michael O'Riordan

May 16, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.